Press "Enter" to skip to content

Takeda unlikely to sell OTC drug business – CEO

Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire.

Original source:

Also Read:   FDA green lights AstraZeneca's asthma drug Fasenra for self-administration